Share Agilent earnings preview: can lab demand sustain margin gains? — November 23, 2026

EARNINGS & CATALYSTS · November 19, 2026

Agilent earnings preview: can lab demand sustain margin gains? — November 23, 2026

Agilent reports after close on November 23. Watch laboratory demand, profit margins without tariff refunds and how its completed Proscia acquisition shapes the new fiscal year.

By Stocks To Buy Now AI Research · Published

90
Financials
Technicals
Earnings & peers
Earnings calendar snapshot · dates in New York time
CompanyReport dateWindowEPS estimateRevenue estimate
Agilent Technologies, Inc. (A)November 23, 2026Issuer confirmedAfter close1.731.99B

1) When are results, and what is expected?

Agilent confirmed fiscal fourth-quarter and full-year 2026 results for November 23, 2026 after close. The quarter ended October 31. As checked November 19, the consensus is approximately $1.99 billion in sales and $1.73 in adjusted EPS, or profit per share. These are estimates, not released results. The issuer’s confirmation takes precedence over calendars that still label the date expected.

2) What matters in the business?

In fiscal 2025, Agilent generated $6.948 billion in revenue. CrossLab supplied $2.908 billion, Life Sciences and Diagnostics $2.726 billion and Applied Markets $1.314 billion. Recurring servicing and consumables can cushion uneven instrument orders. Watch whether customers’ replacement spending translates into sustained sales rather than a temporary catch-up.

3) What could change the outlook?

Third-quarter sales were $1.878 billion and adjusted EPS was $1.62, versus consensus of $1.84 billion and $1.49. The $0.06 EPS benefit from tariff refunds means the full improvement should not be extrapolated. Proscia closed on November 4, after fiscal year-end, for $240 million in cash plus up to $30 million in milestone payments. Its software complements pathology instruments, but integration costs and revenue contribution belong in the new-year discussion.

4) What do peers and risks suggest?

Waters reported $1.767 billion of third-quarter revenue and $4.10 adjusted EPS on November 3, with organic revenue growth of 9%. Its $896 million acquired-business contribution makes headline revenue growth a poor direct comparison. For Agilent, equipment budgets, trade costs and the pace of acquisition integration could challenge margins. A strong past quarter does not guarantee a favorable earnings-day stock move.

5) What should investors watch next?

Compare the November 23 results with the $1.98–$2.00 billion sales and $1.71–$1.74 adjusted EPS outlook, then focus on fiscal 2027 guidance. Shares closed at $177.33 on November 18. Recent lows around $170.50–$171.50 and highs near $180–$181.50 are reference areas, not price targets; earnings can create gaps beyond them.

6) How the business makes money

Agilent sells laboratory instruments, software, consumables and services to pharmaceutical, diagnostics and industrial customers. Its installed instrument base supports repeat purchases of supplies and maintenance.

7) What to watch

The next test is whether customer demand and operating improvements sustain profit growth without the third-quarter tariff-refund benefit. The completed Proscia purchase adds digital-pathology software and makes integration and fiscal 2027 guidance important.

8) Recently reported peers

Waters reported on November 3: organic revenue grew 9% and adjusted EPS reached $4.10. That supports a healthier laboratory-spending backdrop, but its acquired businesses contributed $896 million of sales, so total growth is not directly comparable with Agilent.

9) Risks into the report

Customers can delay equipment purchases. Tariffs, currencies and acquisition integration costs can pressure profits, while last quarter’s refunds make headline margin comparisons less straightforward.

10) Insider activity over the past three months

$0 bought and $95.97K sold in reported trades. 0% buy / 100% sell by value. 0 insiders bought only, 1 sold only, and 0 did both.

AI-assisted research. Earnings dates and estimates may change. Estimates are not reported results. Educational information; investing involves risk.

Explore the stocks in this report

EXPLORE COMPANY RESEARCH

Agilent Technologies: the full stock picture

Earnings history, financials, price action and peer comparisons — all below.
Open A stock page ↗

EXPLORE THE COMPANY

Agilent Technologies (A)

Explore earnings, price action, financials and industry comparisons.

Symbol
A
Sector
Healthcare
Industry
Diagnostics & Research
Instrument type
EQUITY

Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.

EARNINGS & COMPANY RESEARCH

A earnings, valuation & price action

View in calendar ↗
NEXT EXPECTED REPORTNov 23 2026After close · ET
EPS ESTIMATE1.73
REVENUE ESTIMATE1.99B

Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.

COMPANY RESEARCH · Healthcare

Agilent Technologies, Inc. A

Medical - Diagnostics & Research · Updated 11/19/2026

Adjusted closing price · USD177.33 Nov 18
107133159185Nov 17May 20Nov 18
Price50-day average200-day average+23.6% in view
VALUATION & EXPECTATIONS
Trailing P/E34.8×
Forward P/E26.4×
Trailing P/S6.8×
Forward P/S6.3×
EPS beat rate75%
Revenue beat rate88%
Positive window75%

EPS beats: 6 of 8 comparable reports. Positive price windows: 6 of 8.

Market caps may be up to 14 days old; prices up to seven days old; ratios and analyst estimates up to fourteen days old. Forward multiples use consensus for the fiscal year ending 2027-10-31, not the next 12 months. Negative or unavailable earnings multiples show “N/A”. Forward ADR multiples are omitted when the currency/share basis is not reconciled.

50-day average169.89
200-day average138.24
RSI (14)55
20-day range171.78 – 181.48
Relative volume1.2×
1-year change+23.6%
Last eight reported earnings for A
Report dateEPS estimateEPS actualSurpriseResultRevenue actualPrice window*5 sessions*
Aug 26 20261.491.62+8.7%Beat1.88B+1.9%-2.2%
May 27 20261.411.49+5.7%Beat1.84B+17.6%+19.4%
Feb 25 20261.371.36-0.7%Miss1.8B-2.8%-3.1%
Nov 24 20251.581.59+0.4%Beat1.84B+3.9%-1.6%
Aug 27 20251.371.370.0%Met1.74B+5.6%+8.6%
May 28 20251.261.31+4.0%Beat1.67B+1.8%+3.3%
Feb 26 20251.281.31+2.3%Beat1.68B-5.3%-5.7%
Nov 25 20241.411.46+3.5%Beat1.7B+0.4%+4.1%

*Adjusted close before the report date to the first (or fifth) trading close after it. This window can span two sessions and is not an isolated earnings-day return. Figures may be revised by the provider.

Smart Money activity

Recent insider and politician transactions, and disclosed fund positions for A.

Get Pro to see what insiders are doing ahead of earnings.

Explore insider trades, fund holdings and politician activity with an active Pro membership.

Checking membership…

A earnings previews and market catalysts

Agilent earnings preview: can lab demand sustain margin gains? — November 23, 2026
2026-11-19 · Agilent reports after close on November 23. Watch laboratory demand, profit margins without tariff refunds and how its completed Proscia acquisition shapes the new fiscal year.

All upcoming earnings catalysts →

02 / FINANCIALS

Agilent Technologies financials

Revenue, earnings, cash flow and financial strength in one view.

Reporting currency unconfirmed.

Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics

Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.

03 / WHAT COMES NEXT

Agilent Technologies event catalysts

Company earnings and scheduled market events that may change expectations.

2026-11-23

A earnings

Watch reported results, management’s outlook and the share-price reaction.

See earnings expectations ↑
2026-11-198:30 AM ET

Initial jobless claims

Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.

Release schedule ↗Scheduled
2026-11-2010:00 AM ET

Consumer sentiment · final

Watch changes in inflation expectations as well as sentiment.

Release schedule ↗Scheduled
2026-11-20Contract-specific cutoff

Monthly options expiration

Check your contract. Position unwinds and hedging can affect trading volume.

Release schedule ↗Scheduled
2026-11-20Time not announced

Russell · membership list update

Track revisions before the effective date; index flows do not guarantee a price rise.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

Durable goods orders

Read core capital-goods orders alongside the headline; aircraft orders can create large swings.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

Initial jobless claims

Use the multiweek trend; a single reading can be noisy. Thanksgiving release moves to Wednesday.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

PCE inflation & consumer spending

Compare core PCE and real spending with expectations to assess inflation alongside demand.

Release schedule ↗Scheduled
2026-11-258:30 AM ET

Q3 GDP · second estimate

Separate consumer demand from inventory and trade effects; revisions can change the growth picture.

Release schedule ↗Scheduled

Dates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.

04 / SIDE BY SIDE

Compare A with its peers

Medical - Diagnostics & Research · Compare valuation, financial strength and price performance.

Companies with valuation data7
Peer median positive P/E36.3×
A P/E34.8×
A peer comparison: valuation
CompanyPriceMarket capP/EForward P/EP/SForward P/S
AAgilent Technologies2026-11-18 · USD177.3349.96B34.8×26.4×6.8×6.3×
BIOBio-Rad Laboratories, Inc.2026-11-18 · USD369.3810.16B10.0×37.9×3.9×3.9×
BRKRBruker Corporation2026-11-18 · USD63.269.72B29.8×2.8×2.7×
DHRDanaher Corporation2026-11-18 · USD228.41160.2B37.2×26.6×6.3×6.1×
MTDMettler-Toledo International Inc.2026-11-17 · USD1,712.9533.64B36.3×36.2×8.0×7.9×
QGENQiagen N.V.2026-11-17 · USD49.7510.44B25.9×20.5×5.0×4.9×
RVTYRevvity, Inc.2026-11-18 · USD152.7317.9B71.0×28.2×6.1×6.2×
A34.8×
BIO10.0×
DHR37.2×
MTD36.3×
QGEN25.9×
RVTY71.0×

The peer median excludes the selected stock and is based on 5 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.

05 / PEER ANALYSIS

Explore A alongside its peers

Diagnostics & Research · 20 companies · Cached market data

Comparison

Compare companies

Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.

Price / sales
1.9×6.55B4.1×99.88B6.4×193.21B8.7×286.54BTMO · Thermo Fisher Scientific Market cap: 259.44B Price / sales: 5.5×DHR · Danaher Market cap: 160.2B Price / sales: 6.3×IQV · IQVIAs Market cap: 43.65B Price / sales: 2.5×MTD · Mettler-Toledo International, I Market cap: 33.64B Price / sales: 8.0×A · Agilent Technologies, Inc. Market cap: 49.96B Price / sales: 6.8×Hide A · Undo restores itMarket cap
AAgilent Technologies, Inc.

Market cap: 49.96B
Price / sales: 6.8×

Valuation snapshot: 2026-11-18
5 of 20 companies have both plotted values.

P/S distribution

Trailing price-to-sales multiples · 5 companies

Median P/S6.3×
Middle 50%5.5× to 6.8×
A P/S6.8×
A
2.3×8.4×

Tap a bar to see the companies in that P/S range. A has a higher P/S than 60% of this group.

15 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.

Companies

Showing 8 of 20 matching companies · Largest market cap first

  • Market cap 259.44BP/E 36.9×P/S 5.5×Forward P/E Forward P/S Price snapshot: 2026-11-18
    ↗
  • Market cap 160.2BP/E 37.2×P/S 6.3×Forward P/E Forward P/S Price snapshot: 2026-11-18
    ↗
  • Market cap 49.96BP/E 34.8×P/S 6.8×Forward P/E Forward P/S Price snapshot: 2026-11-18
    ↗
  • Market cap 44.79BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 43.65BP/E 31.8×P/S 2.5×Forward P/E Forward P/S Price snapshot: 2026-11-17
    ↗
  • Market cap 38.72BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 36.79BP/E P/S Forward P/E Forward P/S Catalog snapshot
    ↗
  • Market cap 33.64BP/E 36.3×P/S 8.0×Forward P/E Forward P/S Price snapshot: 2026-11-17
    ↗

Explore industries

Open an industry for its comparison, valuation and companies.

U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.

How this comparison works

Uses the saved companies from the same industry and listing market, including A, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.

Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.

Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.

INDUSTRY COMPARISON

A industry peers

Diagnostics & Research · Oct 16, 2026 · Closing-price performance

No industry peers are available in the current heatmap coverage.